Type 2 diabetes and glycemic control

Advisory Board member Pamela Dyson underlines the key features for healthcare professionals working in diabetes education, diabetes management, type 2 diabetes prevention, and cardiovascular risk reduction.

Editorial Board member Sanjay Kalra presents his view on the march toward greater integration of digital health technologies and how traditional approaches to diabetes management are already changing.

Nichol AD, Holle MJ, An R. Eur J Clin Nutr 2018. doi: 10.1038/s41430-018-0170-6

The excess mortality risk associated with high or very low glycated hemoglobin values is modified by glycemic variability in diabetes patients aged 70 years or more, shows an analysis of The Health Improvement Network database.

Haneda M et al. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0416-2

Adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin and sulfonylurea treatment may improve glycemic control in patients with type 2 diabetes and high cardiovascular risk, a post-hoc analysis of the EXAMINE trial suggests.

As the utility and availability of devices surges, so too do patient expectations. Advisory Board member Katharine Barnard provides key consultation questions to help determine your patients’ greatest needs and obstacles.

Diabetes nurse consultant and Advisory Board member, Maureen Wallymahmed reflects on her experiences within the profession and charts the evolution of the role over the past 40 years.

The AWARD-10 findings show significantly improved glycemic control in patients with type 2 diabetes who add the glucagon-like peptide-1 receptor agonist dulaglutide to any sodium-glucose cotransporter 2 inhibitor.

Experts review the evidence and best clinical practices of initiating and titrating insulin in patients with type 2 diabetes and provide guidance and practical recommendations for the healthcare community.

Editorial Board member Sanjay Kalra shares his pragmatic and practical suggestions on initiating, monitoring, and titrating suitable patients on U500 regular insulin.

Donihi AC. Curr Diab Rep 2017; 17: 52. doi: 10.1007/s11892-017-0876-1

The 15-year results of the VADT reveal that the legacy cardioprotective effect of intensive glycemic control seen at the 10-year follow-up has now disappeared.